行情

PVCT

PVCT

Provectus Biopha
OTCMQB

实时行情|Nasdaq Last Sale

0.060
+0.004
+6.57%
休市 10:49 05/20 EDT
开盘
0.060
昨收
0.056
最高
0.060
最低
0.060
成交量
1.87万
成交额
1,120
52周最高
0.078
52周最低
0.042
市值
2,516.68万
市盈率(TTM)
-4.0268
分时
5日
1月
3月
1年
5年
暂无数据
暂无数据
了解PVCT最新的财务预测,通过PVCT每股收益,每股净资产,每股现金流等数据分析Provectus Biopha近期的经营情况,然后做出明智的投资选择。
EPS
实际EPS
预期EPS
0.000.000.000.00
    0
Q3 2020
    0
Q4 2020
    0
Q1 2021
    0
Q2 2021
    0
Q3 2021
机构持股
总机构数: 4
机构持股: 13.06万
持股比例: 0.03%
总股本: 4.19亿
类型机构数股数
增持
0
0
建仓
1
1
减持
0
0
平仓
1
2.20万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.64%
制药与医学研究
+1.63%
高管信息
Chairman/Director
Edward Pershing
President
Timothy Scott
Vice Chairman/Director
Dominic Rodrigues
Chief Financial Officer
Heather Raines
Chief Operating Officer/Director
Bruce Horowitz
Chief Technology Officer
Eric Wachter
Director
Webster Bailey
Director
John Lacey
Director
Tim Lu
暂无数据
暂无数据
PVCT 简况
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

微牛提供Provectus Biopharmaceuticals Inc(OTCMQB-PVCT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PVCT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PVCT股票基本功能。